A nitric oxide synthesis inhibitor decreased prostaglandin production in rat mesenteric vasculature

Vascular reactivity is affected by dietary consumption of wild blueberries in the Sprague-Dawley rat

We have previously reported that consumption of blueberry-enriched (BB) diets attenuates the arterial contractile response to alpha(1)-adrenergic stimuli and affects vasomotor tone via endothelium-related pathways. The present study was designed to evaluate vascular function and responsiveness in aortas of weanling male Sprague-Dawley rats fed a control (C) or a BB diet for 7 weeks. Vascular ring studies were conducted in 3-mm isolated rat aortic ring preparations to investigate vasoconstriction induced by L-phenylephrine (Phe) (10(-8)-3 x 10(-6) M) and vasorelaxation induced by acetylcholine (ACh) (10(-8)-3 x 10(-6) M). Agonists were used alone and in the presence of nitric oxide (NO) synthase and cyclooxygenase (COX) inhibitors. We observed a significantly diminished vasoconstrictor response to Phe in aortic rings from rats fed the BB diet. Inhibition of NO synthase but not COX caused a significant increase in the constrictor response in both dietary groups, with the BB group having the greater response. Similarly, the participation of the NO pathway in endothelium-dependent vasorelaxation induced by ACh was greater in the rats fed a BB diet, while COX inhibition showed no effect on maximum ACh-induced vasorelaxation in any diet group. The vessel sensitivity of BB aortic rings to the vasoconstrictor and vasodilator was significantly reduced when compared to controls. We have concluded that diets enriched with blueberries, fed for 7 weeks in Sprague-Dawley rats, seem to affect NO metabolic pathways in the aorta at basal and stimulated levels.

Cyclo-oxygenase inhibition restores the attenuated vasodilation in manganese-deficient rat aorta

Previously we showed that manganese (Mn) deficiency enhances the arterial contractile response to alpha(1) adrenergic stimuli and affects vasomotor tone. The aim of this study was to test the hypothesis that dietary Mn deficiency inhibits the vasodilation pathways of rat aorta. Vascular ring studies were conducted in aortic rings from weanling male Sprague-Dawley rats that were fed either a Mn deficient (MnD) or a Mn adequate/control diet (MnA) (<1 and 12 mg/kg Mn, respectively) for a 14-wk period. We investigated endothelium-dependent vasodilation induced by acetylcholine (Ach; 10(-8) to 3 x 10(-6) mol/L) in isolated 3-mm aortic rings precontracted with l-phenylephrine (l-Phe; 10(-6) mol/L). Seven concentrations of Ach were used in the presence or absence of inhibitors of nitric oxide synthase and cyclo-oxygenase. After a second precontraction, 8 doses of sodium nitroprusside (SNP; 10(-8) to 10(-5) mol/L) were added to assess endothelium-independent vasodilation. We observed a decrease in Ach-induced and SNP-induced vasodilation in MnD rat aortas when compared with MnA rat aortas (P </= 0.05). Vessel sensitivity of MnD and MnA aortas to Ach was similar. The addition of l-arginine had no effect on nitric oxide-mediated vasodilation in either group. Nitric oxide synthase-inhibition blunted endothelium-dependent vasodilation to the same degree for both diet groups. Cyclo-oxygenase inhibition enhanced both Ach-induced and SNP-induced vasodilation of MnD rings compared with MnA aortic rings (P </= 0.05). Manganese inhibits the synthesis or activity of a prostanoid-derived vasoconstrictor, which seems to be present at basal and at stimulated levels. This effect is independent of membrane-related events. Our results provide further information on the critical role of Mn on vasomotor tone.

Interaction between nitric oxide and prostanoids in arterioles of rat cremaster muscle in vivo

We studied in vivo interactions of nitric oxide (NO), oxidative stress, and prostanoids derived from the cyclooxygenase pathway in the arterioles studied by intravital microscopy in peripheral muscle. Topical administration of NO synthase (NOS) inhibitor Nomega-nitro-l-arginine (l-NNA) or cyclooxygenase inhibitor mefenamic acid (MA) alone leads to vasoconstriction. We found that l-NNA after MA induced an additional constriction, whereas MA after l-NNA induced a relative dilation. Therefore, an additional constriction was found when MA was administered after l-NNA in the presence of the thromboxane A2 synthase-PGH2 (TP) receptor antagonist SQ-29548. We also found a relative dilation when the TP receptor antagonist was administered after NOS inhibition by l-NNA. In the presence of superoxide dismutase and catalase, l-NNA-induced vasoconstriction is reduced, and the dilation observed after addition of MA in presence of the reactive oxygen species is no longer present. Taken together, these results showed that NO inhibition induced a shift in the synthesis or in the effects of cyclooxygenase products, in favor of constrictor prostanoids. This effect of NO inhibition disappears when reactive oxygen species are scavenged by superoxide dismutase and catalase.

Sepsis alters vessel contraction by adrenoceptor-induced nitric oxide and prostanoid

BACKGROUND

Alpha-adrenergic agents contract vascular smooth muscle (VSM) and stimulate endothelial release of secondary factors which modulate VSM contraction. Our study examined constrictor prostanoid (cPN) and nitric oxide (NO) as secondary factors which could alter alpha-1 adrenoceptor-mediated contraction during sepsis.

METHODS

Sepsis was induced in rats by inoculation of an implanted sponge with Escherichia coli and Bacteroides fragilis. Aortic rings at 24 h from septic (n = 21) and control (n = 21) rats were suspended in physiological salt solution (PSS) with or without blockers to NO (N(G)-monomethylarginine), cPN (mefenamic acid, MFA), or thromboxane A2 (SQ29548). Contraction dose-response curves were generated to determine maximal contraction force (F(max)) and pD2 (sensitivity) to phenylephrine in each experimental group.

RESULTS

Sepsis increased F(max) to phenylephrine (PHE) (1.18 vs 0.90 g, SEM 0.0703). COX inhibition reduced the F(max) in control (0.63 vs 0.90 g, SEM 0.0675) but not in septic animals (1.19 vs 1.18 g, SEM 0.0433). TXA2 receptor inhibition did not alter F(max) in control (1.017 vs 0.973 g, SEM 0.0959) or septic animals (1.28 vs 1.12 g, SEM 0.0823). NOS inhibition enhanced the F(max) in both nonseptic (2.03 vs 0.83 g, SEM 0.0523) and septic rats (1.96 vs 1.15 g, SEM 0.0526), but did less so in the septic animals.

CONCLUSIONS

PHE-induced F(max) is determined by a balance between PHE-stimulated VSM alpha-adrenoceptor activity, and PHE-stimulated endothelial release of cPN and NO. Sepsis enhances total PHE-induced F(max) by increasing VSM alpha-adrenoceptor activity and reducing PHE-stimulated endothelial release of dilator NO. Sepsis abolishes the PHE-stimulated endothelial release of cPN. PHE-stimulated cPN is not thromboxane A2, but could be a nonprostanoid dilator in the lipoxygenase (HETE) or cytochrome P450 (EET) pathways.

Nitric oxide inhibits norepinephrine-induced hepatic vascular responses but potentiates hepatic glucose output

We previously reported that sympathetic nerve-induced vasoconstriction in the intestine resulted in shear stress induced release of nitric oxide (NO) that led to presynaptic inhibition of transmitter release. In contrast, studies in the liver suggested a postsynaptic inhibition of vascular responses, thus leading to the hypothesis tested here that maintained catecholamine release in the liver would result in maintained metabolic catecholamine action in the face of inhibition of vascular responses. In rats, norepinephrine (NE) induced elevations in arterial glucose content were inhibited by NO synthase antagonism (Nω-nitro-L-arginine methyl ester (L-NAME), 10 mg/kg, intraportal) but potentiated by NO donor administration (3-morpholinosydnonimine (SIN-1), 0.2 mg/kg, intraportal). The potentiated effect of SIN-1 was abolished by indomethacin (7.5 mg/kg, intraportal). To confirm the hepatic site of metabolic effect, cats were used so that blood flow and hepatic glucose balance could be determined. SIN-1 potentiated NE-induced glucose output from the liver from 5.0 ± 0.4 to 7.2 ± 0.6 mg·min-1·kg-1. The potentiation was blocked by methylene blue, a guanylate cyclase inhibitor. Contrary to the glucose response, L-NAME potentiated but SIN-1 attenuated NE-induced portal vasoconstriction. Thus NO is shown to produce differential modulation of vascular and metabolic effects of NE. Vasoconstriction of the hepatic vasculature is inhibited by NO, whereas the glycogenolytic response to NE is potentiated, responses that are probably mediated by prostaglandin.Key words: prostaglandin, glucose, portal vasculature, Nω-nitro-L-arginine methyl ester, 3-morpholinosydnonimine.

The effect of indomethacin and prostacyclin agonists on blood pressure in a rat model of preeclampsia

OBJECTIVE

This study was designed to determine the effects of cyclooxygenase inhibition and prostacyclin agonists on the hypertension induced by nitric oxide synthase blockade in a previously characterized rat model of preeclampsia.

STUDY DESIGN

A condition similar to preeclampsia was induced by infusing pregnant rats with the nitric oxide synthase inhibitor N G -nitro- L -arginine methyl ester through subcutaneously implanted osmotic minipumps. Blood pressure was measured with the tail cuff method. In the first experiment the rats received either vehicle alone (control group), N G -nitro- L -arginine methyl ester (50 mg/d), indomethacin (0.1 mg/d), or N G -nitro- L -arginine methyl ester plus indomethacin beginning on day 17 of pregnancy. In the second experiment the rats received vehicle alone (control group), N G -nitro- L -arginine methyl ester (50 mg/d), or N G -nitro- L -arginine methyl ester plus iloprost (31 microgram/d). In a third experiment cicaprost (15 microgram/d) was substituted for iloprost.

RESULTS

Except for an increase on the day after insertion of the pump indomethacin had no significant effect on the hypertension induced by N G -nitro- L -arginine methyl ester. Both prostacyclin agonists (iloprost and cicaprost), however, attenuated the rise in blood pressure usually seen after N G -nitro- L -arginine methyl ester administration.

CONCLUSIONS

Nonselective inhibition of the cyclooxygenase enzymatic system does not influence the hypertension seen in the rat preeclampsia model induced by chronic nitric oxide deficiency. The hypertension in this model can be partially reversed with prostacyclin analogs.

Inhibition by auranofin of the production of prostaglandin E2 and nitric oxide in rat peritoneal macrophages

In rat peritoneal macrophages, 12-O-tetradecanoylphorbol 13-acetate (TPA) (16.2 nM) stimulated production of both prostaglandin E2 and nitric oxide. TPA also increased the levels of mRNA for cyclooxygenase-2 and inducible nitric oxide synthase, suggesting that the increase in the production of prostaglandin E2 and nitric oxide is due to the increase in the levels of mRNA for cyclooxygenase-2 and inducible nitric oxide synthase, respectively. The TPA-induced increase in prostaglandin E2 production was partially inhibited by the inhibitor of nitric oxide synthase L-N(G)-monomethyl-L-arginine acetate (L-NMMA), and the TPA-induced increase in nitric oxide production was partially inhibited by the cyclooxygenase inhibitor indomethacin, suggesting that both the production of prostaglandin E2 and nitric oxide in TPA-stimulated macrophages is influenced by each other. The orally active chrysotherapeutic agent auranofin, at 3 and 10 microM, inhibited the TPA-stimulated production of prostaglandin E2 and nitric oxide, and suppressed the TPA-induced increase in the levels of mRNA for cyclooxygenase-2 and inducible nitric oxide synthase. These findings indicate that the inhibition by auranofin of the TPA-stimulated production of prostaglandin E2 and nitric oxide is due to the decrease in the levels of mRNA for cyclooxygenase-2 and inducible nitric oxide synthase, respectively, and the interaction of the production between prostaglandin E2 and nitric oxide may partly be involved in the mechanism for the inhibition by auranofin of the production of both prostaglandin E2 and nitric oxide.

Production of eicosanoids and angiotensin II in resistance vessels in spontaneously hypertensive rats

1. Angiotensin II (AngII) and eicosanoids may be important in vascular remodelling and the pressor response via autocrine and paracrine mechanisms. We evaluated the influences of ageing and beta-adrenoceptor stimulation on the production of vascular AngII and eicosanoids in male spontaneously hypertensive rats (SHR), aged 5, 17 and 30 weeks, and age-matched Wistar-Kyoto (WKY) rats. 2. All rats were weighed and their systolic blood pressure (SBP) was measured by the tail-cuff method. Mesenteric arteries were isolated and perfused with Krebs'-Henseleit solution. The outflows of prostaglandin E2 (PGE2), 6-keto-PGF1 alpha, thromboxane B2 (TxB2) and AngII were measured by specific radioimmunoassays. 3. The SBP was higher in SHR than in WKY rats in the 17- and 30-week-old groups and increased with age. Basal levels of PGE2 were significantly lower in SHR than in WKY rats. The ratios of 6-keto-PGF1 alpha to TxB2 and PGE2 to TxB2 were significantly lower in 17-week-old SHR compared with age-matched WKY rats. Basal AngII release did not differ between SHR and WKY rats and decreased with age. Isoproterenol stimulated the release of AngII; the magnitude of the increment was greater in WKY rats than in age-matched SHR. These results show that there is an imbalance in the production of vasodilator and vasoconstrictor eicosanoids in the resistance vessels of SHR at ages at which hypertension developed. 4. This imbalance may contribute to the increased vasoconstrictor response and vascular remodelling in SHR. Our findings suggest that vascular AngII plays a role in the ageing process and that beta-adrenoceptor-stimulated release of vascular AngII is impaired in SHR.